MarkWide Research

Sale!

Cancer Immunotherapy Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: August, 2022
No of Pages: 168
Delivery Format: PDF + Excel

$2,950.00

Cancer Immunotherapy Market Overview 2030:

The cancer immunotherapy market size was estimated at $85,603.50 Million in 2020 and is predicted to rise to $309,667.65 million by 2030, registering a CAGR of 14.1 percent from 2021 until 2030.

Cancer immunotherapy treatment is a treatment that boosts the immune system’s capacity to combat cancer. It is superior to the traditional method because it offers long-term protection against cancer, has fewer harmful side effects, and can treat more cancer types. It is employed for various cancers like prostate cancer, melanoma, colorectal cancer, breast cancer, lung cancer, cancer of the head and neck, and many more. Immunotherapy involves redirecting the immune system towards specific cancerous targets by stimulating the immune system, causing it to move towards the targeted area, and then triggering an immune response capable of eliminating cancerous cells.

There are many reasons, including the rise in healthcare costs, increase in cancer incidence and the increasing availability of medical insurance, and a surge in advancements in cancer treatments that are expected to boost the growth of the global market for cancer immunotherapy. According to the statistics provided by national cancer institutes, in 2020 there were 1,806,590 new instances of cancer have been discovered within the U.S., and 606,520 people died due to cancer. This increase in the number of cases of cancer is expected to boost the development of the market over the coming years. Awareness programs that raise awareness about the necessity of chemotherapy for cancer are expected to assist in growth over the forecast time. However, other elements like the strict guidelines for cancer immunotherapy could limit the expansion of the market for cancer immunotherapy. The government is more supervised regarding treatments using immunotherapy. It is also in charge of clinical trials that are based according to the regulations of the government, making it difficult for businesses to get into the market and, consequently, is expected to slow the market’s growth. Additionally, the high development costs are expected to hinder the expansion of the market for cancer immunotherapy.

Cancer Immunotherapy Market  Report Scope and Segmentation 
 
ATTRIBUTESDETAILS
ESTIMATED YEAR2022
BASE YEAR2021
FORECAST YEAR2030
HISTORICAL YEAR2017-2021
UNITValue (USD Million/Billion)
BY REGIONNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

Global Cancer Immunotherapy Market Segmentation

The cancer immunotherapy market is divided by technology type, type of end-user, application, and regions. Based on the type of technology, the market is classified into monoclonal antibodies, cytokines, and immunomodulators, as well as others. Monoclonal antibodies accounted for the most market share in 2020 due to the increase in the use of monoclonal antibodies in cancer immunotherapy since they have distinct properties that allow the immune system function can be altered and thus affect or block the immune system. Additionally, monoclonal antibodies can also trigger the antitumor immune response.

According to the application, the cancer immunotherapy market can be classified into breast cancer, lung cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancers, and other uses. The market for lung cancer held the biggest percentage in 2020 and is predicted to be the leading market in the period of analysis due to the prevalence of lung cancer in the world as well as an increase in awareness programs about the need for early treatment for lung cancer.

Based on the end consumer, the market can be divided into cancer research centers and clinics. Hospitals had the highest market share of cancer immunotherapy in 2020, and the segment is predicted to have the highest growth rate throughout the analysis because of the widespread utilization of cancer immunotherapy within hospitals. Additionally, the increased preference for hospitals is predicted to accelerate the growth of this segment over the forecast timeframe. In addition, the hospital’s segment will increase the highest CAGR of around 14.7 percent over the forecast timeframe.

TheHospitalssegment led the market until 2020 and is now.

Regionally, the cancer immunotherapy market is studied throughout North America, Europe, Asia-Pacific, and LAMEA. North America was the highest income contributor in 2020. This is due to the dramatic increase in the amount spent on healthcare, the increased emphasis on maintaining the highest quality healthcare systems, and the rising prevalence of cancer worldwide. But Asia-Pacific is projected to expand at the fastest CAGR throughout the study period due to the rise in healthcare expenses, an increase in per-capita income, and improvements in the healthcare infrastructure. Furthermore, Europe is expected to be the second-largest revenue contributor over the forecast period due to the growth of the region’s infrastructure and the rising incidence of cancer.

The main players in the cancer immunotherapy market are Amgen, Inc., AstraZeneca, PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lily and Company, F. Hoffmann-La Roche, Ltd. (Genentech, Inc.), Pfizer, Inc., Johnson & Johnson (Janssen Global Services LLC), Merck KGAA, and Novartis AG.

Key Benefits for Stakeholders

  • The study offers a comprehensive review of the cancer immunotherapy market size and current developments, and future estimates to help understand the upcoming investment opportunities.
  • It presents a market analysis for 2021 through 2030. It is expected to allow all users to profit from the opportunities that are present in the immunotherapy for cancer market
  • An in-depth analysis of the regions helps in understanding the market within the region, helps in the business plan for strategic purposes, and identifying opportunities that are in the market.
  • The growth strategies and profiles of the leading players are thoroughly examined for comprehending the worldwide competitive outlook for the cancer immunotherapy market.

Key Market Segments

By Technology Type

  • Monoclonal Antibodies
  • Cytokines & Immunomodulators
  • Others

By Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head & Neck Cancer
  • Others

By End-User

  • Hospitals
  • Cancer Research Centers
  • Clinics

Regional Analysis

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Italy
    • France
    • UK
    • Spain
    • Poland
    • Russia
    • The Netherlands
    • Norway
    • Czech Republic
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Malaysia
    • Thailand
    • Singapore
    • Australia & New Zealand
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Northern Africa
    • Rest of MEA

List of the key actors profiled by the publication

  • Amgen, Inc.
  • AstraZeneca, PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lily And Company
  • F. Hoffmann-La Roche, Ltd. (Genentech, Inc.)
  • Pfizer, Inc.
  • Johnson & Johnson (Janssen Global Services, LLC)
  • Merck KGAA
  • Novartis AG

Table of Contents

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porters five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in prevalence of cancer diseases
3.5.1.2.Rise in geriatric population
3.5.1.3.Growth in awareness among consumers regarding cancer immunotherapy
3.5.1.4.Increase in expenditure for the healthcare sector

3.5.2.Restraints

3.5.2.1.Risk of allergic reaction and limitations of the cancer immunotherapy treatment
3.5.2.2.Stringent government regulations

3.5.3.Opportunity

3.5.3.1.Increasing research and development in cancer immunotherapy
3.5.4.Impact analysis

3.6.Impact analysis of COVID-19 on the cancer immunotherapy market

CHAPTER 4:CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Monoclonal antibodies

4.2.1.Market size and forecast, by region
4.2.2.Market analysis, by country

4.3.Cytokines & Immunomodulators

4.3.1.Market size and forecast, by region
4.3.2.Market analysis, by country

4.4.Others

4.4.1.Market size and forecast, by region
4.4.2.Market analysis, by country

CHAPTER 5:CANCER IMMUNOTHERAPY MARKET, BY APPLICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Lung Cancer

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Breast Cancer

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Colorectal Cancer

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Melanoma

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

5.6.Prostate Cancer

5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country

5.7.Head & Neck Cancer

5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country

5.8.Others

5.8.1.Market size and forecast, by region
5.8.2.Market analysis, by country

CHAPTER 6:CANCER IMMUNOTHERAPY MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospitals

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Cancer Research Centers

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Clinics

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:CANCER IMMUNOTHERAPY MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.North America market size and forecast, by technologies type
7.2.2.North America market size and forecast, by application
7.2.3.North America market size and forecast, by end user
7.2.4.North America market size and forecast, by country
7.2.5.U.S.

7.2.5.1.U.S. market size and forecast, by technologies type
7.2.5.2.U.S. market size and forecast, by application
7.2.5.3.U.S. market size and forecast, by end user

7.2.6.Canada

7.2.6.1.Canada market size and forecast, by technologies type
7.2.6.2.Canada market size and forecast, by application
7.2.6.3.Canada market size and forecast, by end user

7.2.7.Mexico

7.2.7.1.Mexico market size and forecast, by technologies type
7.2.7.2.Mexico market size and forecast, by application
7.2.7.3.Mexico market size and forecast, by end user

7.3.Europe

7.3.1.Europe market size and forecast, by technologies type
7.3.2.Europe market size and forecast, by application
7.3.3.Europe market size and forecast, by end user
7.3.4.Europe market size and forecast, by country
7.3.5.Germany

7.3.5.1.Germany market size and forecast, by technologies type
7.3.5.2.Germany market size and forecast, by application
7.3.5.3.Germany market size and forecast, by end user

7.3.6.France

7.3.6.1.France market size and forecast, by technologies type
7.3.6.2.France market size and forecast, by application
7.3.6.3.France market size and forecast, by end user

7.3.7.UK

7.3.7.1.UK market size and forecast, by technologies type
7.3.7.2.UK market size and forecast, by application
7.3.7.3.UK market size and forecast, by end user

7.3.8.Italy

7.3.8.1.Italy market size and forecast, by technologies type
7.3.8.2.Italy market size and forecast, by application
7.3.8.3.Italy market size and forecast, by end user

7.3.9.Spain

7.3.9.1.Spain market size and forecast, by technologies type
7.3.9.2.Spain market size and forecast, by application
7.3.9.3.Spain market size and forecast, by end user

7.3.10.Rest of Europe

7.3.10.1.Rest of Europe market size and forecast, by technologies type
7.3.10.2.Rest of Europe market size and forecast, by application
7.3.10.3.Rest of Europe market size and forecast, by end user

7.4.Asia-Pacific

7.4.1.Asia-Pacific market size and forecast, by technologies type
7.4.2.Asia-Pacific market size and forecast, by application
7.4.3.Asia-Pacific market size and forecast, by end user
7.4.4.Asia-Pacific market size and forecast, by country
7.4.5.Japan

7.4.5.1.Japan market size and forecast, by technologies type
7.4.5.2.Japan market size and forecast, by application
7.4.5.3.Japan market size and forecast, by end user

7.4.6.China

7.4.6.1.China market size and forecast, by technologies type
7.4.6.2.China market size and forecast, by application
7.4.6.3.China market size and forecast, by end user

7.4.7.India

7.4.7.1.India market size and forecast, by technologies type
7.4.7.2.India market size and forecast, by application
7.4.7.3.India market size and forecast, by end user

7.4.8.Rest of Asia-Pacific

7.4.8.1.Rest of Asia-Pacific market size and forecast, by technologies type
7.4.8.2.Rest of Asia-Pacific market size and forecast, by application
7.4.8.3.Rest of Asia-Pacific market size and forecast, by end user

7.5.LAMEA

7.5.1.LAMEA market size and forecast, by technologies type
7.5.2.LAMEA market size and forecast, by application
7.5.3.LAMEA market size and forecast, by end user
7.5.4.LAMEA market size and forecast, by country
7.5.5.Latin America

7.5.5.1.Latin America market size and forecast, by technologies type
7.5.5.2.Latin America market size and forecast, by application
7.5.5.3.Latin America market size and forecast, by end user

7.5.6.Middle East

7.5.6.1.Middle East market size and forecast, by technologies type
7.5.6.2.Middle East market size and forecast, by application
7.5.6.3.Middle East market size and forecast, by end user

7.5.7.Africa

7.5.7.1.Africa market size and forecast, by technologies type
7.5.7.2.Africa market size and forecast, by application
7.5.7.3.Africa market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

8.1.AMGEN, INC.

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance

8.2.ASTRAZENECA, PLC.

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.BAYER AG

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments

8.4.BRISTOL-MYERS SQUIBB COMPANY

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.ELI LILY AND COMPANY

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments

8.6.F. HOFFMANN-LA ROCHE LTD (GENENTECH, INC.)

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.JOHNSON & JOHNSON (Janssen Global Services, LLC)

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.MERCK KGAA

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.NOVARTIS AG

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.PFIZER INC.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.GLOBAL CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY TYPE, 20202030 ($MILLION)
TABLE 02.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR TEMPERATURE PATCH, BY REGION, 20202030 ($MILLION)
TABLE 03.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CYTOKINES AND IMMUNOMODULATORS, BY REGION, 20202030 ($MILLION)
TABLE 04.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY REGION, 20202030 ($MILLION)
TABLE 05.GLOBAL CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030 ($MILLION)
TABLE 06.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HEALTHCARE, BY REGION, 20202030 ($MILLION)
TABLE 07.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR BREAST CANCER, BY REGION, 20202030 ($MILLION)
TABLE 08.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR COLORECTAL CANCER, BY REGION, 20202030 ($MILLION)
TABLE 09.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR MELANOMA, BY REGION, 20202030 ($MILLION)
TABLE 10.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR PROSTATE CANCER, BY REGION, 20202030 ($MILLION)
TABLE 11.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 20202030 ($MILLION)
TABLE 12.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY REGION, 20202030 ($MILLION)
TABLE 13.GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END USER, 20202030 ($MILLION)
TABLE 14.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HOSPITALS, BY REGION, 20202030 ($MILLION)
TABLE 15.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CANCER RESEARCH CENTERS, BY REGION, 20202030 ($MILLION)
TABLE 16.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CLINICS, BY REGION, 20202030 ($MILLION)
TABLE 17.CANCER IMMUNOTHERAPY MARKET, BY REGION, 20202030, ($MILLION)
TABLE 18.NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 19.NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 20.NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY END USE, 20202030, ($MILLION)
TABLE 21.NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 20202030, ($MILLION)
TABLE 22.U.S. CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 23.U.S. CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 24.U.S. CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 25.CANADA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 26.CANADA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 27.CANADA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 28.MEXICO CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 29.MEXICO CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 30.MEXICO CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 31.EUROPE CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 32.EUROPE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 33.EUROPE CANCER IMMUNOTHERAPY MARKET, BY END USE, 20202030, ($MILLION)
TABLE 34.EUROPE CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 20202030, ($MILLION)
TABLE 35.GERMANY CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 36.GERMANY CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 37.GERMANY CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 38.FRANCE CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 39.FRANCE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 40.FRANCE CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 41.UK CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 42.UK CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 43.UK CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 44.ITALY CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 45.ITALY CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 46.ITALY CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 47.SPAIN CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 48.SPAIN CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 49.SPAIN CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 50.REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 51.REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 52.REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 53.ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 54.ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 55.ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY END USE, 20202030, ($MILLION)
TABLE 56.ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 20202030, ($MILLION)
TABLE 57.JAPAN CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 58.JAPAN CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 59.JAPAN CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 60.CHINA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 61.CHINA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 62.CHINA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 63.INDIA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 64.INDIA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 65.INDIA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 66.REST OF ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 67.REST OF ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 68.REST OF ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 69.LAMEA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 70.LAMEA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 71.LAMEA CANCER IMMUNOTHERAPY MARKET, BY END USE, 20202030, ($MILLION)
TABLE 72.LAMEA CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 20202030, ($MILLION)
TABLE 73.LATIN AMERICA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 74.LATIN AMERICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 75.LATIN AMERICA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 76.MIDDLE EAST CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 77.MIDDLE EAST CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 78.MIDDLE EAST CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 79.AFRICA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 80.AFRICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 81.AFRICA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 82.MEDTRONIC: COMPANY SNAPSHOT
TABLE 83.AMGEN: OPERATING SEGMENTS
TABLE 84.AMGEN: PRODUCT PORTFOLIO
TABLE 85.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 86.ASTRAZENECA INC.: OPERATING SEGMENTS
TABLE 87.ASTRAZENECA INC.: PRODUCT PORTFOLIO
TABLE 88.BAYER : COMPANY SNAPSHOT
TABLE 89.BAYER : OPERATING SEGMENT
TABLE 90.BAYER : PRODUCT PORTFOLIO
TABLE 91.BMS: COMPANY SNAPSHOT
TABLE 92.BMS: PRODUCT PORTFOLIO
TABLE 93.ELI LILLY: COMPANY SNAPSHOT
TABLE 94.LILLY: OPERATING SEGMENTS
TABLE 95.ELI LILLY: PRODUCT PORTFOLIO
TABLE 96.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97.ROCHE: COMPANY SNAPSHOT
TABLE 98.ROCHE : OPERATING SEGMENTS
TABLE 99.ROCHE : PRODUCT PORTFOLIO
TABLE 100.ROCHE : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101.J&J: COMPANY SNAPSHOT
TABLE 102.J&J: OPERATING BUSINESS SEGMENTS
TABLE 103.J&J: PRODUCT PORTFOLIO
TABLE 104.J&J : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105.MERCK: COMPANY SNAPSHOT
TABLE 106.MERCK: OPERATING SEGMENTS
TABLE 107.MERCK: PRODUCT PORTFOLIO
TABLE 108.NOVARTIS: COMPANY SNAPSHOT
TABLE 109.NOVARTIS: OPERATING SEGMENT
TABLE 110.NOVARTIS : PRODUCT PORTFOLIO
TABLE 111.PFIZER: COMPANY SNAPSHOT
TABLE 112.PFIZER: OPERATING SEGMENT
TABLE 113.PFIZER: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.GLOBAL CANCER IMMUNOTHERAPY MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 20182021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 20182021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 20182021
FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07.HIGH BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR TEMPERATURE PATCH, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CYTOKINES AND IMMUNOMODULATORS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR LUNG CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR BREAST CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR MELANOMA, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CANCER RESEARCH CENTERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CLINICS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 26.AMGEN: NET SALES, 20182020 ($MILLION)
FIGURE 28.AMGEN: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 29.ASTRAZENECA: NET SALES, 20182020 ($MILLION)
FIGURE 30.ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 31.ASTRAZENECA: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 32.BAYER : NET SALES, 20182020 ($MILLION)
FIGURE 33.BAYER: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 34.BAYER: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 35.BMS: NET SALES, 20182020 ($MILLION)
FIGURE 36.BMS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 37.ELI LILLY: NET SALES, 20182020 ($MILLION)
FIGURE 38.ELI LILLY: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 39.ELI LILLY: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40.ROCHE: NET SALES, 20182020 ($MILLION)
FIGURE 41.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 42.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 43.J&J: NET SALES, 20182020 ($MILLION)
FIGURE 44.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 45.J&J: REVENUE SHARE BY REGION, 2020(%)
FIGURE 46.MERCK: NET SALES, 2018-2020 ($MILLION)
FIGURE 47.MERCK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 48.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 49.NOVARTIS: NET SALES, 20182020 ($MILLION)
FIGURE 50.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 51.NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 52.PFIZER: NET SALES, 20182020 ($MILLION)
FIGURE 53.PFIZER: REVENUE SHARE, BY REGION, 2020 (%)

Major Companies

  • Amgen, Inc.
  • AstraZeneca, PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lily And Company
  • F. Hoffmann-La Roche, Ltd. (Genentech, Inc.)
  • Pfizer, Inc.
  • Johnson & Johnson (Janssen Global Services, LLC)
  • Merck KGAA
  • Novartis AG

Major Segmentation

By Technology Type

  • Monoclonal Antibodies
  • Cytokines & Immunomodulators
  • Others

By Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head & Neck Cancer
  • Others

By End-User

  • Hospitals
  • Cancer Research Centers
  • Clinics

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF